Work

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-129168

Authors: Namrata S Chandhok, Wei Wei, Ranjit Bindra, Stephanie Halene, Yu Shyr, Jing Li, Michael Berens, Chris Karlovich, S. Percy Ivy, Thomas Prebet

Institutions: Yale New Haven Hospital, Cleveland Clinic, Yale University, Yale Cancer Center, Vanderbilt University, The Barbara Ann Karmanos Cancer Institute, Translational Genomics Research Institute, Frederick National Laboratory for Cancer Research, National Cancer Institute

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2985043323

Cites:

Cited by: 7

Related to: 10